CollPlant VP lists options and RSUs in Form 3

CollPlant Biotechnologies Ltd executive Philippe Bensimon reported his initial ownership in a Form 3.

Rhea-AI Filing Summary

CollPlant Biotechnologies Ltd executive Philippe Bensimon reported his initial ownership in a Form 3. As VP Regulations and QA, he lists direct holdings of options to purchase ordinary shares in four grants covering 9,000, 15,000, 21,000 and 30,000 underlying shares at exercise prices of $4.0200 and $6.3900 per share. He also holds 2,000 ordinary shares, plus 30,000 restricted share units, of which 13,125 are already vested and the remaining 16,875 vest in nine equal quarterly installments from June 8, 2026 through June 8, 2028, subject to continued service.

Insider Trade Summary

6 transactions reported

Mixed 6 txns

Insider Bensimon Philippe

Role VP Regulations and QA

Type	Security	Shares	Price	Value
holding	Options to Purchase Ordinary Shares	--	--	--
holding	Options to Purchase Ordinary Shares	--	--	--
holding	Options to Purchase Ordinary Shares	--	--	--
holding	Options to Purchase Ordinary Shares	--	--	--
holding	Ordinary Shares	--	--	--
holding	Restricted Share Units	--	--	--

Holdings After Transaction: Options to Purchase Ordinary Shares — 75,000 contracts (Direct); Ordinary Shares — 2,000 shares (Direct); Restricted Share Units — 30,000 shares (Direct)

Footnotes (3)

1. F1. To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued to an employee or director in connection with the Issuer's Share Ownership and Option Plan (2010) or 2024 Share Award Plan must be registered in the name of a trustee.
2. F2. Of the restricted share units reported herein, 13,125 units are vested, and the remaining 16,875 units vest in nine equal quarterly installments beginning June 8, 2026 and ending June 8, 2028, subject to the Reporting Person's continued service to the Issuer as of such vesting date.
3. F3. Fully vested and exercisable.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the CLGN Form 3 filing by Philippe Bensimon show?

The Form 3 shows Philippe Bensimon’s initial ownership in CollPlant Biotechnologies Ltd. It lists his direct holdings of options on ordinary shares, 2,000 ordinary shares, and 30,000 restricted share units, giving investors a clear view of his current equity-based compensation position.

How many CollPlant (CLGN) options does Philippe Bensimon report on Form 3?

Bensimon reports four option grants to purchase ordinary shares. These cover 9,000 and 15,000 shares at an exercise price of $4.0200, and 21,000 and 30,000 shares at $6.3900. Each grant has its own expiration date between 2027 and 2032.

What CollPlant (CLGN) restricted share units does Philippe Bensimon hold?

He holds 30,000 restricted share units. According to the filing, 13,125 units are already vested. The remaining 16,875 units vest in nine equal quarterly installments from June 8, 2026 to June 8, 2028, contingent on continued service with CollPlant.

How many CollPlant (CLGN) ordinary shares does Philippe Bensimon directly own?

The Form 3 shows direct ownership of 2,000 ordinary shares of CollPlant Biotechnologies Ltd. These stand alongside his option holdings and restricted share units, forming part of his overall equity exposure to the company’s performance over time.

Are Philippe Bensimon’s CollPlant (CLGN) equity awards fully vested?

No, they are partially vested. All reported option grants are described as fully vested and exercisable, but only 13,125 of his 30,000 restricted share units are vested. The remaining 16,875 vest quarterly between June 2026 and June 2028, subject to continued service.

Why are CollPlant (CLGN) employee securities held through a trustee?

The filing explains that, for Israeli tax benefits under Section 102, securities issued under CollPlant’s 2010 Share Ownership and Option Plan or 2024 Share Award Plan must be registered in a trustee’s name. This structure supports favorable tax treatment for employees and directors.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/18/2026 - 10:12 AM Learn about SEC filing dates

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Bensimon Philippe

(Last) (First) (Middle)

C/O COLLPLANT BIOTECHNOLOGIES LTD.

4 OPPENHEIMER ST, WEIZMANN SCIENCE PARK

(Street)

REHOVOT 7670104

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
CollPlant Biotechnologies Ltd [ CLGN ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	VP Regulations and QA

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Ordinary Shares(1)	2,000	D
Restricted Share Units(1)	30,000(2)	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Options to Purchase Ordinary Shares(1)(3)	05/18/2016	05/18/2028	Ordinary Shares	9,000(3)	$4.02	D
Options to Purchase Ordinary Shares(1)(3)	12/26/2018	12/26/2027	Ordinary Shares	15,000(3)	$4.02	D
Options to Purchase Ordinary Shares(1)(3)	05/26/2021	05/26/2030	Ordinary Shares	21,000(3)	$6.39	D
Options to Purchase Ordinary Shares(1)(3)	01/27/2023	01/27/2032	Ordinary Shares	30,000(3)	$6.39	D

Explanation of Responses:

1. To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued to an employee or director in connection with the Issuer's Share Ownership and Option Plan (2010) or 2024 Share Award Plan must be registered in the name of a trustee.

2. Of the restricted share units reported herein, 13,125 units are vested, and the remaining 16,875 units vest in nine equal quarterly installments beginning June 8, 2026 and ending June 8, 2028, subject to the Reporting Person's continued service to the Issuer as of such vesting date.

3. Fully vested and exercisable.

	/s/ Philippe Bensimon	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)